Effectiveness of 18F-FDG PET/CT in finding lung metastasis from a retroperitoneal paraganglioma

Document Type : Case report


1 Department of Radiology, Kurume University School of Medicine, Kurume, Japan

2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

3 Department of Surgery, Kurume University School of Medicine, Kurume, Japan

4 Department of Surgery, Kurume University School of Medicine, Kurume, Japan.

5 Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan


A 50-year-old woman was diagnosed with iron deficiency anemia on general medical examination. Further, contrast-enhanced abdominal CT and magnetic resonance imaging revealed a large hypervascular mass with internal degeneration and necrosis in the retroperitoneal space. She was referred to our hospital for further evaluation and treatment. Because the paraganglioma was most likely as the imaging diagnosis, 123I-MIBG scintigraphy was performed. It revealed the marked abnormal accumulation in the retroperitoneal lesion indicating the paraganglioma and no other abnormal accumulation was noted. Several plasma catecholamines and their urinary metabolites were normal. On the subsequent 18F-FDG PET/CT, high FDG uptake was found in the retroperitoneal lesion (SUVmax=38). FDG uptake was also found in a small nodule at the base of the lower lobe of the right lung (SUVmax= 9.8). Contrast-enhanced imaging revealed a hypervascular nodule at the base of the right lung, suggesting pulmonary metastasis of a paraganglioma. The abdominal lesion and right lung nodule were excised, and retroperitoneal paraganglioma and pulmonary metastasis were diagnosed based on the pathology findings. In this case, 18F-FDG PET/CT was useful in the search for paraganglioma metastasis. We report a relationship between 123I-MIBG accumulation and 18F-FDG uptake in paraganglioma and review the relevant literature.


Main Subjects

  1. Choi YM, Sung TY, Kim WG, Lee JJ, Ryu JS, Kim TY, et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. J Surg Oncol. 2015; 112(8):815-821.
  2. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromo-cytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012; 104(9):700-708.
  3. Lau D, La Marca F, Camelo-Piragua S, Park P. Metastatic paraganglioma of the spine: case report and review of the literature. Clin Neurol Neurosurg. 2013; 115(9):1571-1574.
  4. Fries JG, Chamberlin JA. Extra-adrenal pheochromocytoma: Literature review and report of a cervical pheochromocytoma. Surgery. 1968; 63:268-275.
  5. WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine tumours, vol. 8. 5th (International Agency for Research on Cancer, Lyon, France, 2022) https:// tumour classification. Iarc.who.int. Accessed 10 May 2023.
  6. Mikhail RA, Moore JB, Reed DN Jr, Abbott RR. Malignant retroperitoneal para- J Surg Oncol. 1986; 32(1): 32-36.
  7. Lam AK. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. 2017; 28(3):213-227.
  8. Huang KH, Chung SD, Chen SC, Chueh SC, Pu YS, Lai MK, et al. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute. Int J Urol. 2007; 14(3):181-185.
  9. Angelousi A, Kassi E, Zografos G, Kaltsas G. Metastatic pheochromocytoma and para-ganglioma. Eur J Clin Invest. 2015; 45(9): 986-997.
  10. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002; 26(5):551-566.
  11. Kulkarni MM, Khandeparkar SG, Deshmukh SD, Karekar RR, Gaopande VL, Joshi AR, et al. Risk Stratification in paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and immunohistochemical markers. J Clin Diagn Res. 2016; 10(9):EC01-EC04.
  12. Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma. Nucl Med Mol Imaging. 2015; 49(2):143-51.
  13. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6–18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-meta-iodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010; 95(6):2800-2810.
  14. Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012; 19(1):83-93.
  15. Van Berkel A, Pacak K, Lenders JW. Should every patient diagnosed with a phaeochromocytoma have a ¹²³I-MIBG scintigraphy? Clin Endocrinol (Oxf). 2014; 81(3):329-333.
  16. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013; 98(1):E162-E73.